Patients living with multiple myeloma across England and Wales should now get ‘routine’ access to Amgen’s Kyprolis on the NHS within three months following a final green light from the National Institute for Health and Care Excellence.
Read More
The National Institute for Health and Care Excellence is backing routine NHS use of Amgen’s Kyprolis as an option for treating patients with multiple myeloma at first relapse.
Read More
Cost regulators for the NHS in England and Wales are not recommending Amgen’s Kyprolis as a cost-effective use of resources.
Read More
